| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | 0.028 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |